Azebiotics is a privately held Danish pharmaceutical company exclusively committed to discovery and development of novel antibiotics to treat multidrug-resistant infections.

The company was founded in 2019 based on the serendipitous discovery of a small molecule with antimicrobial effect. This discovery has subsequently been transformed into the finding of a completely new class of potent antibiotics against several MDR bacteria.